Skip to search boxSkip to navigationSkip to main content

Quality Attributes and In Vitro Bioequivalence of Amlodipine (5 mg) Tablets in Ica, Peru

  • Jorge A. García
    ,
  • María R. Bendezú
    ,
  • ,
  • Ana María Muñoz
    ,
  • María Saravia
    ,
  • Angel T. Alvarado
  • Universidad Nacional San Luis Gonzaga de Ica
    ,
  • Peruvian Association of Immunogenomics and Personalized Medicine
    ,
  • Universidad San Ignacio de Loyola
Research Output: Contribution to journal Article Peer-review

Open access

Publication Information

Output type

Research Output: Contribution to journal Article Peer-review

Original language

English

Journal (Volume, Issue Number)

Dissolution Technologies (Volume 28, Issue 4)

Publication milestones

  • Published - 11/2021

Publication status

Published - 11/2021

ISSN

1521-298X

Publication IDs

  • Scopus: 85122461163

Abstract

Dissolution studies have evolved from quality control testing to being an indicator of biopharmaceutical performance and an alternative to in vivo bioequivalence and interchangeability studies in clinical practice. The critical quality attributes and in vitro bioequivalence of two generic formulations of amlodipine (5-mg tablets, A and B) were compared to the reference (Ref) drug. Amlodipine tablets available in Ica, Peru belong to class 1. The study evaluated weight, hardness, friability, and content of the tablets. USP apparatus 2 was used with 900 mL of dissolution medium at pH 1.2, 4.5, and 6.8. 5 (100 rpm, 37 ± 0.5 °C). Samples (5 mL) were withdrawn at 5, 10, 15, 20, 25, 30, 45, and 60 min and analyzed at 239 nm on a spectrophotometer. The dissolution percentages at pH 4.5 and 6.8 were less than 85% at 30 min for all three products; at pH 1.2, more than 85% was released in less than 15 min (Ref: 101.6%; A: 98.5%, B: 89.9%). The similarity factors were 51.2–64.3; dissolution efficiency was 84.5–96.5%, and mean dissolution time was 4.5–12.4 min. According to these parameters, generic formulations A and B demonstrated in vitro bioequivalence to the reference drug.